Archive · 2 Jun 2025
Court Bans Semaglutide Sales by Dr. Reddy's and OneSource
The Delhi High Court stopped Dr. Reddy's and OneSource from selling the drug semaglutide in India after Novo Nordisk said they were infringing on its patent.
This means the companies can't sell the drug in India for now, but they can still make and send it out of the country.
Novo Nordisk says their patent is valid and wants to protect their invention.
The companies' stock prices dropped a bit because of this.
The court case is ongoing, and the companies aren't commenting.
Semaglutide helps with diabetes.
The drug will go off patent in Canada in 2026.
Delhi High Court barred Dr. Reddy's and OneSource from selling semaglutide in India.
The ruling followed a patent infringement claim by Novo Nordisk.
The companies can still manufacture and export the drug.
Shares of both companies declined up to 3% after the ruling.
Novo Nordisk's semaglutide patents are protected in India, expecting continued protection.
- Who
- Dr. Reddy's Laboratories, OneSource, and Novo Nordisk are the main companies involved.
- What
- The Delhi High Court banned Dr. Reddy's and OneSource from selling semaglutide in India due to patent infringement.
- When
- The Delhi High Court issued the ban on Friday, June 2. Dr. Reddy's began producing semaglutide in April 2025.
- Where
- The ban applies to sales within India, originating from the Delhi High Court.
- Why
- The court ruled in favor of Novo Nordisk, which claimed that Dr. Reddy's and OneSource were infringing on its patent for semaglutide.
Dr. Reddy's and OneSource
Novo Nordisk
Patent Validity and Infringement
Dr. Reddy's and OneSource
Dr. Reddy's and OneSource are likely to argue they are not infringing on the patent, as they sought revocation of the patent in court.
Novo Nordisk
Novo Nordisk asserts its patents are protected in India and that Dr. Reddy's and OneSource are infringing on their intellectual property rights.
- Court
- Delhi High Court
- Drug
- Semaglutide
- Plaintiff
- Novo Nordisk
- Claim
- Patent Infringement
- Sales Ban Location
- India
- Patent Expiry (Canada)
- January 2026